Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update LYMPHIR commercial availability planned for the fourth quarter of 2025 FISCAL THIRD QUARTER 2025 FINANCIAL HIGHLIGHTS: ● On July 17, 2025, Citius Oncology completed a public offering generating net proceeds of approximately 7.4 million, after deducting placement agent fees and other offering expenses; ● R&D expenses were 938,000 for the quarter ended June 30, 2025, as compared to $1.1 millio ...